T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take aim at tough T-Cell cancers
Disease control Recruiting nowThis early-phase trial tests a new cell therapy for people with T-cell leukemia or lymphoma that has come back or not responded to treatment. Researchers take a patient's own T-cells, add a special receptor (CD7.CAR) to help them recognize and attack cancer cells, and give them b…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated May 17, 2026 03:30 UTC
-
New hope for tough T-Cell cancers: immunotherapy after transplant shows promise
Disease control Recruiting nowThis early-phase trial tests whether adding the immunotherapy drug daratumumab after a stem cell transplant is safe for children, teens, and young adults with high-risk T-cell acute lymphoblastic leukemia or lymphoma. About 30 participants will receive the drug after standard tra…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: New York Medical College • Aim: Disease control
Last updated May 17, 2026 03:30 UTC
-
Engineered immune cells take on tough T-Cell cancers
Disease control Recruiting nowThis study tests a new treatment called CD7 CAR T-cell therapy for people with T-cell cancers (leukemia or lymphoma) that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells or cells from a donor, which are modified to find and at…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 17, 2026 03:25 UTC
-
Engineered immune cells target stubborn leukemia in new trial
Disease control Recruiting nowThis study tests a treatment called WU-CART-007 for people with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that has come back or not responded to other treatments. The therapy uses donor immune cells that are modified to find and attack cancer cells. The main g…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Wugen, Inc. • Aim: Disease control
Last updated May 17, 2026 03:23 UTC
-
New hope for T-ALL patients: drug targets stubborn leukemia cells
Disease control Recruiting nowThis study tests a drug called daratumumab in people with T-cell acute lymphoblastic leukemia (T-ALL) whose cancer cells remain or return after standard chemotherapy. The goal is to see if the drug can wipe out these leftover cancer cells and lead to remission. About 20 adults wi…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Eastern Cooperative Oncology Group • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Engineered immune cells target hard-to-treat t-cell cancers in early trial
Disease control Recruiting nowThis early-phase trial tests whether specially engineered immune cells (anti-CCR9 CAR T cells) made from a patient's own blood are safe and what dose works best. It includes children and adults with T-cell acute lymphoblastic leukemia or lymphoma that has come back or not respond…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: University College, London • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug duo shows promise against tough leukemia
Disease control Recruiting nowThis study tests whether combining two drugs, venetoclax and azacitidine, can help people newly diagnosed with T-cell acute lymphoblastic leukemia (T-ALL). About 28 participants aged 15 and older will receive the treatment to see how many achieve remission. The goal is to find a …
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Supercharged immune cells take aim at tough T-Cell cancers
Disease control Recruiting nowThis early-phase study tests a new treatment for people with T-cell leukemia or lymphoma that has come back. The therapy uses the patient's own (or their donor's) immune cells, which are modified in the lab to better recognize and attack cancer cells. The goal is to see if this a…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated May 04, 2026 16:32 UTC
-
Promising drug cocktail targets tough blood cancers in kids
Disease control Recruiting nowThis study tests whether a combination of three drugs (calaspargase pegol-mknl, decitabine, and venetoclax) can help control relapsed or treatment-resistant T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LLy) in patients aged 1 month to 21 years.…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 01, 2026 15:58 UTC
-
Engineered immune cells take on tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a new treatment called CD1a-CAR T cells for people with T-cell acute lymphoblastic leukemia or lymphoma that has come back or not responded to standard therapy. The treatment involves taking a patient's own immune cells, modifying them to recognize an…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: OneChain Immunotherapeutics • Aim: Disease control
Last updated Apr 26, 2026 19:37 UTC
-
New hope for kids with aggressive leukemia: trial tests powerful drug combos
Disease control Recruiting nowThis study is testing whether adding one of two targeted drugs, dasatinib or venetoclax, to standard chemotherapy can improve outcomes for children and young adults with newly diagnosed T-cell leukemia or lymphoma. The main goal is to see if more patients achieve a deep, early re…
Matched conditions: T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Apr 15, 2026 16:16 UTC